<DOC>
	<DOCNO>NCT00292396</DOCNO>
	<brief_summary>The purpose study assess safety efficacy ABT-874 treatment moderate severe chronic plaque psoriasis .</brief_summary>
	<brief_title>Efficacy Safety ABT-874 Subjects With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subject age 18 old good health ( Investigator discretion ) recent stable medical history . Subject clinical diagnosis psoriasis least 6 month , moderate severe plaque psoriasis Subject previously receive systemic biologic antiIL12 therapy Subject discontinue systemic therapy and/or topical therapy treatment psoriasis avoid UVB PUVA phototherapy Subject take require oral injectable corticosteroid Subject consider investigator , reason , unsuitable candidate study Female subject pregnant breastfeeding consider become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>